This company listing is no longer active
Zymergen Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Información clave
-13.0%
Tasa de crecimiento de los beneficios
68.1%
Tasa de crecimiento del BPA
| Crecimiento de la industria Chemicals | 12.9% |
| Tasa de crecimiento de los ingresos | -22.1% |
| Rentabilidad financiera | -154.2% |
| Margen neto | -2,503.0% |
| Última actualización de beneficios | 30 Jun 2022 |
Actualizaciones de resultados anteriores recientes
Recent updates
Zymergen chief scientific officer to depart as company lays off more employees
Aug 25Zymergen: Ginkgo Bioworks Acquisition
Jul 26Zymergen expands agreement with Octant on developing breakthrough medicines
Jul 14Zymergen Seeks Turnaround But Runway Is Running Low
Jun 03Zymergen: A Humbled Company With A Business On The Ropes
May 23Some Zymergen Inc. (NASDAQ:ZY) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 27
Zymergen Inc. (NASDAQ:ZY) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 25Zymergen: Total Chaos
Dec 09Zymergen: How To Buy A Disaster
Aug 05Analysts Just Made A Major Revision To Their Zymergen Inc. (NASDAQ:ZY) Revenue Forecasts
Aug 05Zymergen acquired Accelerator Life Science Partners’ portfolio company
May 28Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Zymergen. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 22 | 15 | -365 | 104 | 0 |
| 31 Mar 22 | 18 | -349 | 107 | 0 |
| 31 Dec 21 | 17 | -362 | 106 | 0 |
| 30 Sep 21 | 20 | -359 | 98 | 0 |
| 30 Jun 21 | 19 | -323 | 95 | 0 |
| 31 Mar 21 | 14 | -281 | 85 | 0 |
| 31 Dec 20 | 13 | -262 | 78 | 0 |
| 31 Dec 19 | 15 | -237 | 85 | 0 |
Ingresos de calidad: ZY is currently unprofitable.
Margen de beneficios creciente: ZY is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Insufficient data to determine if ZY's year-on-year earnings growth rate was positive over the past 5 years.
Acelerando crecimiento: Unable to compare ZY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: ZY is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (20.9%).
Rentabilidad financiera
Alta ROE: ZY has a negative Return on Equity (-154.22%), as it is currently unprofitable.